MedTrace Logo

Evaluate the Potential of Montelukast to Prevent Nasal Symptomatology During Colds

NCT00189475 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2020-11-18

Study results available
· View outcomes & findings →

Summary

Assesses the efficacy of treatment with montelukast 10 mg PO QD x 5 days versus placebo for the treatment of viral-induced upper respiratory infection in healthy adults aged 18-50 years.

Conditions

  • Upper Respiratory Infection

Interventions

DRUG

Montelukast

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Deborah Gentile, MD · West Penn Allegheny Health System

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-10-31
Primary Completion
2007-07-31
Completion
2007-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00189475 on ClinicalTrials.gov